In the first of 400 suits to be tried over the acne drug Accutane’s propensity to cause inflammatory bowel disease, an Atlantic County, N.J., jury has assessed $2.62 million in damages against Hoffmann-La Roche Inc. and its Swiss parent company.

However, the jury of six women and four men did not award punitive damages under New Jersey’s Consumer Fraud Act because they found insufficient evidence the manufacturer intentionally failed to warn the drug can cause IBD.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]